← Back to Search

18F-Fluciclovine for Cervical Cancer

Phase 4
Waitlist Available
Led By Bital Savir-Baruch, M.D
Research Sponsored by Bital Savir-Baruch
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
GYN cancer (ovarian, endometrial, or cervical) was biopsy-proven and/or schedule for subsequent surgery based on clinical presentation (imaging, markers)
Age ≥ 18 years.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 30
Awards & highlights

Study Summary

This trial is evaluating the use of 18F-fluciclovine in women with gynecological cancers.

Eligible Conditions
  • Cervical Cancer
  • Endometrial Cancer
  • Ovarian Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 30
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
18F-Fluciclovine uptake in gynecologic neoplasms

Trial Design

1Treatment groups
Experimental Treatment
Group I: 18F-FluciclovineExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fluciclovine (18F)
FDA approved

Find a Location

Who is running the clinical trial?

Bital Savir-BaruchLead Sponsor
Blue Earth DiagnosticsIndustry Sponsor
38 Previous Clinical Trials
2,987 Total Patients Enrolled
Bital Savir-Baruch, M.DPrincipal Investigator - Nuclear Medicine Assistant Professor
Gottlieb Memorial Hospital, Loyola University Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Mar 2025